Methodology
Order Report via our
online store
or via order form
|
Products, Technologies and Markets Worldwide in the Report S800
s 268 pages s 81 Exhibits s 34 Company Profiles s Published October 2004 s Report #S800 This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient worldwide population in obesity, detailing their incidence, the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report will detail the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products worldwide. The report profiles 34 companies in this market, detailing the current products, products in development, market position and overall businesses in obesity management. Table of Contents Executive Summary
Section 1: Introduction
Section 2: Weight loss management approaches
Section 3: Impact of obesity
Section 4: Clinical trends
Section 5: Products & Technologies
Section 6: Market Assessment
Section 7: Opportunities
Section 8: Company Profiles
Appendix: List of Companies ABBREVIATIONS
Exhibit ES-1: Worldwide Obesity Devices Market Forecast, 2002-2013 (US$M) Exhibit 1-1: Relationship Between BMI and Risk of Disease Exhibit 1-2: Elements Contributing to the Obesity Epidemic Exhibit 1-3: Prevalence of Obesity, Percent of Population (2003) Exhibit 1-4: WHO Graph of Obesity, 2004 Exhibit 1-5: Worldwide Total, Obese and Morbidly Obese, 2002-2013 Exhibit 1-6: Examples of Definitions Used and Age Groups Included in Surveys Reporting Prevalence of Obesity Exhibit 1-7: Examples of Human Pleiotropic Obesity Syndromes Exhibit 1-8: Leptin’s Role in the Body Exhibit 1-9: Candidate Genes for Control of Appetite, Energy Expenditure, Usage of Nutrients and Body Fat Distribution Exhibit 2-1: IFSO and Minimum Professional Requirements for the Practicing Bariatric Surgeon Exhibit 2-2: Gastric Bypass Surgery Exhibit 3-1: Examples of Annual National Costs of Obesity (US$ Millions) Exhibit 3-2: Examples of US Insurance Company Obesity Coverage Policies Exhibit 5-1: Bariatric Surgery Procedures in Use and Under Development Exhibit 5-2: Market Shares of Companies in Bariatric Surgery Devices Exhibit 5-3: Pharmaceutical Products Currently on the Market and Under Development Exhibit 5-4: Market Shares of Meridia and Xenical, 2004 Exhibit 5-5: Gastric Stimulation Devices Currently on the Market and Under Development Exhibit 5-6: Brain Stimulation Devices Currently on the Market and Under Development Exhibit 5-7: Radio-Frequency Antralplasty Devices Currently on the Market and Under Development Exhibit 5-8: Combination Therapies Currently on the Market and Under Development Exhibit 5-9: Genetic Therapies Currently on the Market and Under Development Exhibit 6-1: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M) Exhibit 6-2: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M) Exhibit 6-3: Bariatric Surgery Devices, Total Market Forecast, 2002-2013 Exhibit 6-4: Total Bariatric Surgery Devices Market Forecast, 2002-2013 (US$M) Exhibit 6-5: Bariatric Surgery Devices, Market Forecast, United States and Canada, 2002-2013 Exhibit 6-6: Bariatric Surgery Devices, Market Forecast, US and Canada, 2002-2013 Exhibit 6-7: US Obesity Treatment Medical Device Company Market Shares, 2013 Exhibit 6-8: Bariatric Surgery Devices, Market Forecast, European Union, 2002-2013 Exhibit 6-9: Bariatric Surgery Devices, Country Market Shares, European Union, 2004 Exhibit 6-10: Bariatric Surgery Devices, Market Forecast, United Kingdom, 2002-2013 Exhibit 6-11: Bariatric Surgery Devices, Market Forecast, United Kingdom 2002-2013 Exhibit 6-12: Bariatric Surgery Devices, Market Forecast, France, 2002-2013 Exhibit 6-13: Bariatric Surgery Devices, Market Forecast, France, 2002-2013 Exhibit 6-14: Bariatric Surgery Device Market Shares, France, 2004 Exhibit 6-15: Bariatric Surgery Devices, Market Forecast, Germany, 2002-2013 Exhibit 6-16: Bariatric Surgery Devices, Market Forecast, Germany 2002-2013 Exhibit 6-17: Bariatric Surgery Device Market Shares, Germany, 2004 Exhibit 6-18: Bariatric Surgery Devices, Market Forecast, Italy, 2002-2013 Exhibit 6-19: Bariatric Surgery Devices, Market Forecast, Italy 2002-2013 Exhibit 6-20: Bariatric Surgery Devices, Market Forecast, Spain, 2002-2013 Exhibit 6-21: Bariatric Surgery Devices, Market Forecast, Spain 2002-2013 Exhibit 6-22: Bariatric Surgery Devices, Market Forecast, Scandinavia, 2002-2013 Exhibit 6-23: Bariatric Surgery Devices, Market Forecast, Scandinavia 2002-2013 Exhibit 6-24: Bariatric Surgery Devices, Market Forecast, Japan, 2002-2013 Exhibit 6-25: Bariatric Surgery Devices, Market Forecast, Japan 2002-2013 Exhibit 6-26: Bariatric Surgery Devices, Market Forecast, Rest of World, 2002-2013 Exhibit 6-27: Bariatric Surgery Devices, Market Forecast, ROW 2002-2013 Exhibit 6-28: Total Pharmaceutical Sales, Market Forecast, 2002-2013 Exhibit 6-29: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013 Exhibit 6-30: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013 Exhibit 6-31: Obesity Drugs, Market Forecast, European Union, 2002-2013 Exhibit 6-32: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013 Exhibit 6-33: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013 Exhibit 6-34: Obesity Drugs, Market Forecast, France, 2002-2013 Exhibit 6-35: Obesity Drugs, Market Forecast, France, 2002-2013 Exhibit 6-36: Obesity Drugs, Market Forecast, Germany, 2002-2013 Exhibit 6-37: Obesity Drugs, Market Forecast, Germany, 2002-2013 Exhibit 6-38: Obesity Drugs, Market Forecast, Italy, 2002-2013 Exhibit 6-39: Obesity Drugs, Market Forecast, Italy, 2002-2013 Exhibit 6-40: Obesity Drugs, Market Forecast, Spain, 2002-2013 Exhibit 6-41: Obesity Drugs, Market Forecast, Spain, 2002-2013 Exhibit 6-42: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013 Exhibit 6-43: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013 Exhibit 6-44: Obesity Drugs, Market Forecast, Japan, 2002-2013 Exhibit 6-45: Obesity Drugs, Market Forecast, Japan, 2002-2013 Exhibit 6-46: Obesity Drugs, Market Forecast, ROW, 2002-2013 Exhibit 6-47: Obesity Drugs, Market Forecast, ROW, 2002-2013 Exhibit 7-1: Alliance Opportunities Exhibit 8-1: Abbott Laboratories 2003 Sales by Division Exhibit 8-2: Johnson & Johnson and Subsidiaries, Division of Sales by Segment, 2003 Exhibit 8-3: Inamed Corporation Sales, 2003 Exhibit 8-4: Johnson & Johnson Worldwide Sales, 2003 Exhibit 8-5: Johnson & Johnson Sales by Geographic Region, 2003 Exhibit 8-6: Pfizer Divisions by Revenues, Fourth Quarter 2003 Exhibit 8-7: Pfizer Drug Division Revenues as Percent of Total Human Pharmaceutical Revenues, Fourth Quarter 2003 Exhibit 8-8: Roche Sales by Region, 2003 Exhibit 8-9: Sanofi-Aventis 2003 Consolidated Sales Exhibit 8-10: Synovis Life Technologies Sales by Product Group, 2003
|
Products, Technologies and Markets Worldwide in the Clinical Management of Obesity
Report #S800, October 2004
Price
$2,450 for print or PDF; $2,650 for both. (Add $1,500 for site license) [what's this?]
Order report online or via downloadable order form.
| Methodology. MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development. Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports. |
Contact: Patrick Driscoll, (949) 859-3401.
Copyright © 2001-2004, MedMarket Diligence, LLC. All rights
reserved.
Revised: 07/15/08